Can-Fite BioPharma (CANF)
XASE:CANF
Want to see CANF full AI Analyst Report?
Top Page
Can-Fite BioPharma
(NYSE MKT:CANF)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.50
▼(-13.37% Downside)
Action:Reiterated
Date:03/28/26
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
Positive Factors
Conservative balance sheet / low leverage
Very low debt relative to equity materially reduces near-term solvency risk and gives management flexibility to prioritize R&D rather than servicing interest. Over a 2–6 month horizon this conservatism lowers bankruptcy risk and preserves optionality for strategic partnerships or staged financings.
Negative Factors
Persistent negative cash flow
Chronic negative operating and free cash flow increases dependence on external capital and shortens effective runway without material near-term commercialization. Over 2–6 months this structural cash burn raises the probability of further financing rounds that can be dilutive or expensive.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low debt relative to equity materially reduces near-term solvency risk and gives management flexibility to prioritize R&D rather than servicing interest. Over a 2–6 month horizon this conservatism lowers bankruptcy risk and preserves optionality for strategic partnerships or staged financings.
Read all positive factors
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.32M
Dividend YieldN/A
Average Volume (3M)258.05K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.90
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.17K
Enterprise Value/Revenue15.30K
Enterprise Value/Gross Profit15.30K
Enterprise Value/Ebitda-962.05
Forecast
1Y Price Target
$6.00Price Target Upside48.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Can-Fite BioPharma Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, w...
How the Company Makes Money
null...
Can-Fite BioPharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.00K | 408.21K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 560.00K | 384.02K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -8.90M | -10.00M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -8.80M | -9.91M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 90.00K | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.54M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.18M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -9.02M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -8.35M | -9.02M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -2.00K | -2.02K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.08M | 9.72M | 6.71M | 9.14M | 0.00 | 20.46M |
Can-Fite BioPharma Technical Analysis
Negative
4.04
Price Trends
3.23
Positive
3.78
Negative
6.99
Negative
Market Momentum
0.04
Negative
48.59
Neutral
29.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 4.04 is above the 20-day moving average (MA) of 3.23, above the 50-day MA of 3.23, and below the 200-day MA of 6.99, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 48.59 is Neutral, neither overbought nor oversold. The STOCH value of 29.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can-Fite BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $10.24M | -1.45 | -317.47% | ― | -100.00% | 59.83% | |
44 Neutral | $7.56M | -0.49 | -281.30% | ― | ― | 86.07% | |
41 Neutral | $7.32M | ― | ― | ― | ― | ― | |
40 Underperform | $4.66M | -2.45 | -154.50% | ― | ― | 59.90% |
* Healthcare Sector Average
CANF
Can-Fite BioPharma
3.46
-17.14
-83.20%
GNPX
Genprex
0.79
-13.11
-94.32%
BCDA
BioCardia
0.92
-0.96
-51.06%
PCSA
Processa Pharmaceuticals
2.61
-3.42
-56.72%
PHGE
BiomX
0.37
-9.71
-96.29%
Can-Fite BioPharma Corporate Events
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
May 13, 2026
On May 13, 2026, Can-Fite BioPharma announced that, following positive interim results from its ongoing Phase 2a trial in advanced pancreatic adenocarcinoma, it plans to advance its oral A3 adenosine receptor agonist Namodenoson into a Phase 2b st...
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
Apr 30, 2026
On April 30, 2026, Can-Fite BioPharma reported positive Phase 2a data for its A3 adenosine receptor agonist namodenoson in advanced pancreatic cancer, showing preliminary clinical activity and durable disease stabilization in a heavily pretreated ...
Can-Fite BioPharma Sets May 28, 2026 AGM to Vote on Share Capital Increase and Executive Option Grants
Apr 23, 2026
On April 23, 2026, Can-Fite BioPharma announced it will hold its 2026 Annual General Meeting of Shareholders on May 28, 2026, at its Ramat Gan headquarters, with shareholders of record as of May 4, 2026, entitled to vote in person or by proxy. The...
Can-Fite and Vetbiolix Complete Phase 2 Enrollment for Canine Osteoarthritis Drug Piclidenoson
Mar 30, 2026
On March 30, 2026, Can-Fite BioPharma announced that its veterinary partner Vetbiolix completed enrollment of 118 client-owned dogs in a randomized, double-blind, placebo-controlled Phase 2 trial of Piclidenoson for osteoarthritis, with treatment ...
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
Mar 26, 2026
On March 26, 2026, Can-Fite BioPharma reported its 2025 results and recent clinical milestones, highlighting that a Phase 2a trial in heavily pretreated pancreatic cancer patients met its primary safety endpoint, with over 30% of patients alive at...
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Mar 17, 2026
On March 17, 2026, Can-Fite BioPharma announced that the Israeli Patent Office allowed its patent application covering the use of A3 adenosine receptor agonists, including lead candidate Namodenoson, for fat loss and treatment of obesity and relat...
Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting
Mar 10, 2026
On March 10, 2026, Can-Fite BioPharma held a Special General Meeting of Shareholders at which investors approved all three proposals that had been put to a vote, each receiving the required majority. The measures, originally outlined in a January ...
Can-Fite BioPharma Secures $4 Million via Repriced Warrant Exercise to Fund Clinical Pipeline
Mar 5, 2026
On March 4, 2026, Can-Fite BioPharma entered a definitive inducement agreement with a warrant holder for the immediate cash exercise of outstanding warrants to purchase 795,869 ADSs, cutting the exercise price from $9.34 to $5.00 per ADS. The tran...
Can-Fite’s Namodenoson Clears Phase 2a Safety Bar in Advanced Pancreatic Cancer
Mar 4, 2026
On March 4, 2026, Can-Fite BioPharma reported that its Phase 2a open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma who had failed prior systemic therapies successfully met its primary endpoint of safety. Nam...
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
Mar 4, 2026
On March 3, 2026, Can-Fite BioPharma Ltd. convened a Special General Meeting of Shareholders in Ramat Gan, Israel, but the session could not proceed due to a lack of quorum. As a result, the company adjourned the gathering for one week and schedul...
Can-Fite Showcases Namodenoson Anti-Obesity Data in Peer-Reviewed Journal
Feb 17, 2026
On February 17, 2026, Can-Fite BioPharma reported a peer-reviewed publication in the International Journal of Obesity showing that its lead drug namodenoson has a significant anti‑obesity effect in preclinical models. The study found that na...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.